Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, is pleased to announce the appointment of Katherine Cornish-Bowden as a non-executive director with immediate effect.
Kate (44) is a Chartered Financial Analyst and holds a Masters in Business Administration. She was managing director and head of Morgan Stanley Investment Management’s Global Core Equity Team between 2002 and 2004. Prior to this she was an executive director and senior portfolio manager within the same team at Morgan Stanley. More recently Kate has acted as a consultant providing financial research to private equity and financial training firms and was appointed a director of Investec Structured Products Calculus VCT plc in February 2011.
Kate was formerly a director of KCB Research Limited which was voluntarily removed from the Register of Companies on 12 August 2009.
There are no other requirements to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.
David Evans commented "I very much welcome Kate onto Scancell's Board, we are fortunate to have been able to attract someone of Kate's calibre and she will make an invaluable contribution to the Scancell Board going forward."
For further information contact:
Scancell Holdings Plc
Professor Lindy Durrant/Dr Richard Goodfellow
+ 44 (0)207 245 1100
Hansard Communications- Financial PR
Adam Reynolds/Guy McDougall
+ 44 (0)207 245 1100
Zeus Capital - Nominated Adviser
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512
XCAP Securities Plc - Broker
Jon Belliss/Parimal Kumar
+44 (0) 207 101 7070
About Scancell
Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine SCIB1, which entered clinical trials in 2010, is being developed for the treatment of melanoma.
Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.
An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of both helper and CTL responses.
The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.